Actions and spectrum:
sparsentan is an investigational drug used to treat focal segmental glomerulosclerosis (FSGS) and IgA nephropathy. It is a dual endothelin receptor antagonist (ERA) and angiotensin receptor blocker (ARB), meaning that it blocks both the endothelin and angiotensin receptors in the body.
This combination of mechanisms of action may provide a more comprehensive approach to treating certain kidney diseases. sparsentan is thought to reduce proteinuria, or the excessive excretion of protein in the urine, which is a hallmark feature of FSGS and other kidney diseases.
